Location History:
- Vienna, AT (2013)
- Guntramsdorf, AT (2016)
Company Filing History:
Years Active: 2013-2016
Title: Frank Stephan Kalthoff: Innovator in Pharmaceutical Chemistry
Introduction
Frank Stephan Kalthoff is a notable inventor based in Vienna, Austria. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific kinases involved in various diseases. With a total of two patents to his name, Kalthoff's work is recognized for its potential impact on medical treatments.
Latest Patents
Kalthoff's latest patents include an innovative oxazolidin-2-one-pyrimidine derivative, which is designed for the treatment of conditions, diseases, and disorders dependent upon PI3 kinases. This invention focuses on compounds that act as inhibitors of phosphatidylinositol-3-kinase (PI3K), along with pharmaceutical compositions and methods for their manufacture. Another significant patent involves the use of 1H-imidazo[4,5-]quinolinone derivatives in treating protein and/or lipid kinase dependent diseases. This patent outlines methods for administering these derivatives to warm-blooded animals, particularly humans, and includes pharmaceutical preparations for effective treatment.
Career Highlights
Frank Stephan Kalthoff is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on innovative solutions in drug development, contributing to advancements in therapeutic options for patients.
Collaborations
Kalthoff has collaborated with esteemed colleagues such as Pascal Furet and Robert Mah. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical compounds.
Conclusion
Frank Stephan Kalthoff's contributions to pharmaceutical chemistry through his patents and work at Novartis AG highlight his role as an influential inventor in the field. His innovative approaches to treating diseases dependent on specific kinases demonstrate the potential for significant advancements in medical treatments.